Venus Remedies gets coveted GMP certification from Libya

Venus Remedies, a globally recognised pharmaceutical company, has been awarded the Good Manufacturing Practices (GMP) certification for its facilities from the Ministry of Health, Libya. This accomplishment is a testament to the company's commitment to quality, safety and efficiency in the production of injectable pharmaceuticals, including oncology, antibiotic and anticoagulant medications.

Saransh Chaudhary, CEO of Venus Medicine Research Centre, said, " The GMP certification from Libya adds to Venus Remedies' portfolio of international approvals from 25 regulators, complementing our existing certifications in Africa from Morocco, South Africa, Tanzania, Kenya, Uganda, Sudan and other African countries. This GMP certification reflects our collaborative efforts in the African pharmaceutical industry, a key focus area of our global expansion strategy.”

This recognition demonstrates Venus Remedies’ persistence in adhering to stringent manufacturing standards across its global operations and is in line with the company’s commitment to enhancing healthcare solutions that benefit people the world over.

Libya’s pharmaceutical imports, valued at US$ 514 million in 2021, have grown at a rate of 2.81% over the previous year. Its strategic location in Africa and evolving pharmaceutical landscape provide Venus Remedies with an opportunity to contribute positively to the region's healthcare sector. The $46.8 billion pharmaceutical market of Africa, as in 2022, is expected to grow at a CAGR of 8.3% to reach $110.9 billion by 2023. This certification is a step towards enhancing the company's presence in Africa, aligning with its broader vision of improving access to life-saving medicines across the continent.

Lauding the achievement, Akshansh Chaudhary, executive director of Venus Remedies, said, "We are thankful to our customers, partners and stakeholders for their constant support. Their trust in our company drives our pursuit of excellence."

Venus Remedies continues to contribute to global healthcare, aiming to improve public health standards in Libya and other regions in line with its mission of advancing healthcare solutions worldwide.

Panchkula-based Venus Remedies Ltd is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!